PI
FATE icon

Putnam Investments’s Fate Therapeutics FATE Stock Holding History

Putnam Investments’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$915K Buy
244,684
+111,434
+84% +$263K ﹤0.01% 854
2023
Q3 		$282K Buy
+133,250
New +$441K ﹤0.01% 1079

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Putnam Investments's FATE Position: Q4 2023 in Review

Putnam Investments increased its Fate Therapeutics (FATE) stake by 84% in Q4 2023, buying an estimated $263K and bringing the position to 244,684 shares worth $915K. The position accounts for ﹤0.01% of the portfolio, ranked #854.

Putnam Investments first reported a position in FATE in Q3 2023 and has held it in 2 quarters since. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2023.

  • Putnam Investments held 244,684 shares of Fate Therapeutics worth $915K as of Q4 2023.
  • Putnam Investments bought 111,434 Fate Therapeutics shares in Q4 2023, an estimated $263K.
  • Fate Therapeutics made up ﹤0.01% of Putnam Investments's portfolio in Q4 2023, its #854 holding.
  • Putnam Investments first reported a position in Fate Therapeutics in Q3 2023 and has held it in 2 quarters since.
  • 159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2023.

Based on Putnam Investments's 13F filing for Q4 2023, filed 14 Feb 2024.